ALNY - Alnylam Pharmaceuticals, Inc.
| Previous Close | 118.79 |
| Open | 118.17 |
| Bid | 0.00 x 800 |
| Ask | 135.61 x 900 |
| Day's Range | 117.34 - 121.20 |
| 52 Week Range | 60.27 - 125.72 |
| Volume | 449,393 |
| Avg. Volume | 720,921 |
| Market Cap | 13B |
| Beta (5Y Monthly) | 2.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.71 |
| Earnings Date | Feb 5, 2020 - Feb 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 124.95 |
- American City Business Journals
Sanofi to restructure Newton diabetes startup Onduo, saying it 'over-invested'
Sanofi’s new CEO laid out plans Tuesday to shake up one of the Bay State’s biggest drug companies, potentially throwing its 3-year-old diabetes-focused startup Onduo for a loop.
- Zacks
Trade of the 2020's: Sell Gold, Buy Biotech
In 5 years, you be selling your gold and buying more companies leading the century of biology.
- Insider Monkey
Alnylam Pharmaceuticals, Inc. (ALNY): These Hedge Funds Cashed Out Too Early
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of September 30. In this […]
- Simply Wall St.
Alnylam Pharmaceuticals (NASDAQ:ALNY) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- Zacks
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG
- Zacks
Alnylam Gets Second Product Approval Amid Stiff Competition
Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.
- Zacks
Why Gold is Headed to Zero -- And What You Should Buy Instead
Why Gold is Headed to Zero -- And What You Should Buy Instead
- Zacks
Alnylam Pharmaceuticals, Inc. (ALNY) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Alnylam Pharmaceuticals, Inc. (ALNY).
- TEST Business Wire Releases
Alnylam to Webcast Presentations at Upcoming December Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
- Zacks
The Medicines Company to be Acquired by Novartis for $9.7B
The Medicines Company (MDCO) agrees to the $85 per share or $9.7-billion acquisition offer from Novartis.
- Barrons.com
Novartis Is Buying The Medicines Company for $9.7 Billion
Shares of The Medicines Company were up nearly 23% on Monday after Novartis said Sunday that it had agreed to buy the single-drug, clinical-stage biotech company for $85 per share.
- Business Wire
Alnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, is hosting an R&D Day in New York City today. During the event, the Company plans to discuss its commercial and R&D progress, including its product and pipeline goals for 2020, focusing on the potential for global approval and/or commercialization of four RNAi therapeutic products and the advancement of six late-stage investigational programs.
- Zacks
Alnylam's Givosiran Gets FDA Nod for Acute Hepatic Porphyria
Alnylam (ALNY) gets FDA approval for givosiran injection, to be marketed by the trade name of Givlaari, for the treatment of adults with AHP.
- Zacks
Alnylam (ALNY) Catches Eye: Stock Jumps 10.5%
Alnylam (ALNY) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
- Benzinga
The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 20) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY )(announced ...
- MarketWatch
Alnylam shares jump on FDA approval
Shares of Alnylam Pharmaceuticals Inc. were up 9% in afternoon trading after the Food and Drug Administration approved Givlaari, its treatment for acute hepatic porphyria, a rare, genetic metabolic disorder. Patients in the clinical trial who took the drug had fewer porphyria attacks than patients taking a placebo. The annual list price for Givlaari is $575,000 and is dependent on a patient's weight. The biopharmaceutical company also said Wednesday that it has reached a value-based agreement in principle with Harvard Pilgrim, in which the health plan will pay full price for the therapy only if the real-world results match the trials. There are about 3,000 potential patients who have been diagnosed with the genetic disease in the U.S. and Europe, making it an ultra-rare orphan disease. (An orphan disease affects fewer than 200,000 people worldwide.) Alnylam stock has jumped 50% year-to-date, while the S&P 500 has rallied 24%.
- Business Wire
Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI™ (givosiran)
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, is announcing today a new and enhanced framework for value-based agreements (VBAs) designed to help patients with acute hepatic porphyria (AHP) – an ultra-rare orphan disease – gain access to GIVLAARI™ (givosiran) injection for subcutaneous use, a first-of-its-kind RNAi therapeutic for the treatment of AHP. Approved today by the U.S. Food and Drug Administration (FDA), GIVLAARI is indicated for the treatment of adults with AHP. Alnylam is in active discussions with leading payers about VBAs for GIVLAARI and plans to incorporate this new ultra-rare disease framework into these discussions and negotiations.
- Business Wire
Alnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA)
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) approved GIVLAARI™ (givosiran) injection for subcutaneous use for the treatment of adults with acute hepatic porphyria (AHP). AHP is a family of ultra-rare, genetic diseases characterized by debilitating, potentially life-threatening attacks and, for some patients, chronic manifestations that negatively impact daily functioning and quality of life. Long-term complications of AHP can include chronic neuropathic pain, hypertension, chronic kidney disease and liver disease.
- Reuters
UPDATE 2-Alnylam's rare genetic disorder drug priced at $575,000 per year
Alnylam Pharmaceuticals Inc priced its gene silencing drug to treat patients with a rare genetic disorder that can cause severe pain at $575,000 per year after receiving an early U.S. approval on Wednesday. The drug, Givlaari, uses a Nobel Prize-winning mechanism known as RNA interference to target and "silence" specific genetic material and is the second such drug to be approved http://bit.ly/37oqz9Z by the U.S. Food and Drug Administration. The injection, which is dosed based on patient weight, will be available after discounts at $442,000 per year and is approved for acute hepatic porphyria (AHP), a rare disorder that can lead to severe pain and paralysis, respiratory failure and seizures.
- American City Business Journals
FDA gives early OK to Alnylam rare disease drug
The FDA has approved Alnylam's new product Givlaari, which silences the gene behind a rare metabolic disease.
- Zacks
Medicines Company Up on Rumors of Potential Buyout by Novartis
The Medicines Company (MDCO) is rumored to attract acquisition offers after impressive data readouts from three pivotal studies on PCSK9 inhibitor candidate, inclisiran.
- Business Wire
Alnylam Announces Second Annual Advocacy for Impact Grants Program
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that it is accepting applications for its second annual global competitive grants program, Advocacy for Impact. This program aims to provide patient advocacy groups around the world with the flexibility to address the critical unmet needs of the diverse rare disease communities they serve.
